USD
$0.00
(0.00%
)At Close (As of Dec 11, 2025)
$2.20M
Market Cap
-
P/E Ratio
-250.62
EPS
$70.14
52 Week High
$2.02
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$9.6M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $310K |
| Capital Expenditures | $60K |
| Change In Receivables | - |
| Change In Inventory | $279K |
| Profit Loss | - |
| Cashflow From Investment | -$60K |
| Cashflow From Financing | $11M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | $541K |
| Dividend Payout Common Stock | $541K |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$11M |
Sector: HEALTHCARE
Industry: MEDICAL DEVICES
Nuwellis, Inc. is a pioneering medical device company based in Eden Prairie, Minnesota, specializing in ultrafiltration therapy to address fluid overload in patients suffering from heart failure and kidney disease. With its innovative proprietary devices, Nuwellis aims to provide clinicians with effective therapeutic solutions that enhance patient outcomes and overall quality of life. As healthcare increasingly shifts towards targeted and efficient treatment modalities, Nuwellis is well-positioned to capitalize on growing market opportunities, driving sustainable growth in a critical segment of the medical industry.